Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product ... the industry’s 3.1% decline. Zacks Investment Research Image Source: Zacks ...

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product sales ... with the industry’s 3.1% decline. Image Source: Zacks Investment Research ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

with disappointing data for phase 2 drug monlunabant in September and phase 3 GLP-1 and amylin combination cagrisema in December. Novo and Lilly are fighting for share in the global GLP-1 market ...

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has ... 2024 in LA. Getty Images for The Recording Academy She continued, “This is a world that has shamed people for being ...

Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin.

Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin. Yahoo ...

The results come just a few weeks after a once-weekly injectable GLP-1 drug CT-388 – also sourced ... announcement had a similar effect, with the stock up just over 5% at the time of writing.

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit ... cardiovascular events, but the drug effects varied with the patients ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...